NZ592369A - Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment - Google Patents

Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Info

Publication number
NZ592369A
NZ592369A NZ592369A NZ59236909A NZ592369A NZ 592369 A NZ592369 A NZ 592369A NZ 592369 A NZ592369 A NZ 592369A NZ 59236909 A NZ59236909 A NZ 59236909A NZ 592369 A NZ592369 A NZ 592369A
Authority
NZ
New Zealand
Prior art keywords
sequence
fgfr
inhibitors
treatment
methods
Prior art date
Application number
NZ592369A
Other languages
English (en)
Inventor
Haijun Sun
Ling Liu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of NZ592369A publication Critical patent/NZ592369A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ592369A 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment NZ592369A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
NZ592369A true NZ592369A (en) 2013-02-22

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592369A NZ592369A (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Country Status (17)

Country Link
US (3) US8043618B2 (enExample)
EP (1) EP2342232A2 (enExample)
JP (1) JP5577345B2 (enExample)
KR (1) KR101370798B1 (enExample)
CN (2) CN102186884B (enExample)
AR (1) AR073770A1 (enExample)
AU (1) AU2009307841B2 (enExample)
BR (1) BRPI0919832A8 (enExample)
CA (1) CA2741127C (enExample)
EA (1) EA021584B1 (enExample)
IL (1) IL211807A0 (enExample)
MX (1) MX2011004317A (enExample)
NZ (1) NZ592369A (enExample)
TW (1) TWI381848B (enExample)
UA (1) UA101681C2 (enExample)
WO (1) WO2010048026A2 (enExample)
ZA (1) ZA201101938B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
DK3702371T5 (da) 2009-03-25 2024-08-26 Genentech Inc Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
WO2014111744A1 (en) 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
EP3122776B1 (en) 2014-03-25 2021-04-28 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
MX384149B (es) * 2014-09-05 2025-03-14 Hyperfine Inc Aumento ferromagnético para formación de imagenes por resonancia magnética.
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
SG11201706727XA (en) * 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
US20180237424A1 (en) 2015-03-03 2018-08-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fgfr3 antagonists
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
US20180244785A1 (en) * 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
US20240173426A1 (en) * 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
IL322053A (en) 2023-01-13 2025-09-01 Regeneron Pharma FGFR3 binding molecules and methods of using them
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
MX2008014978A (es) * 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
US8192927B2 (en) * 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
ES2453592T3 (es) * 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden

Also Published As

Publication number Publication date
UA101681C2 (ru) 2013-04-25
KR20110056554A (ko) 2011-05-30
US20100098696A1 (en) 2010-04-22
EA021584B1 (ru) 2015-07-30
CA2741127C (en) 2015-06-02
BRPI0919832A8 (pt) 2019-01-08
CN103524620A (zh) 2014-01-22
CN102186884B (zh) 2014-08-13
US20120009200A1 (en) 2012-01-12
AU2009307841B2 (en) 2013-09-12
TWI381848B (zh) 2013-01-11
IL211807A0 (en) 2011-06-30
WO2010048026A3 (en) 2010-07-15
ZA201101938B (en) 2012-08-29
AR073770A1 (es) 2010-12-01
MX2011004317A (es) 2011-06-24
JP2012505912A (ja) 2012-03-08
EP2342232A2 (en) 2011-07-13
WO2010048026A2 (en) 2010-04-29
KR101370798B1 (ko) 2014-03-14
US8182815B2 (en) 2012-05-22
BRPI0919832A2 (pt) 2015-12-15
AU2009307841A1 (en) 2010-04-29
TW201026325A (en) 2010-07-16
CN102186884A (zh) 2011-09-14
US8043618B2 (en) 2011-10-25
US20120219563A1 (en) 2012-08-30
EA201170590A1 (ru) 2011-10-31
CA2741127A1 (en) 2010-04-29
US8404240B2 (en) 2013-03-26
JP5577345B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
NZ592369A (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
NZ603972A (en) Anti-fgfr2 antibodies
NZ596274A (en) Blocking anti-dkk-1 antibodies and their uses
NZ603488A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP4538372A3 (en) Anti-trop2 antibody
NZ610153A (en) Novel anti-dr5 antibody
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
PE20091679A1 (es) Anticuerpo anti-tyrp1
AR061115A1 (es) Anticuerpos anti- interleuquina 18 (il-18)
JP2009102444A5 (ja) 二次性骨腫瘍の治療のための抗PDGFRα抗体
RU2747735C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
NZ602621A (en) Antibodies against csf-1r
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
NZ744185A (en) Antibodies and conjugates thereof
PE20121585A1 (es) ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS
PE20170687A1 (es) Proteinas de enlace a cd127
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
PE20140133A1 (es) Nuevas proteinas de union a antigenos
AR086044A1 (es) Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
NZ584726A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
AR086579A1 (es) Proteinas de union a antigeno
AR081556A1 (es) Proteinas de union al antigeno humanizadas

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 OCT 2016 BY THOMSON REUTERS

Effective date: 20130920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2017 BY THOMSON REUTERS

Effective date: 20160909

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2018 BY THOMSON REUTERS

Effective date: 20170919

LAPS Patent lapsed